Bei Wang

Bei Wang

Auto-generated profile, based on publicly available information

Bei Wang

Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2025 in Science Advances
Verified
Journal Article
Open access
JSJingrong Shao
Jingrong Shao
RXRui Xiao
Rui Xiao
TWTing Wang
Ting Wang
FWFengshuo Wang
Fengshuo Wang
BWBei Wang
Bei Wang
SZShengkai Zuo
Shengkai Zuo
Doxorubicin (DOX) is an effective anticancer drug, but its clinical utility is limited mainly by cardiotoxicity causing cardiomyocyte ferroptosis and apoptosis. While DOX-induced cardiotoxicity (DIC) involves epigenetic changes, no systematic epigenetic intervention studies have been reported. Here, we identified BRD4770 as a potential small molecule against DIC through the Epigenetics Compound Library screening. BRD4770 inhibited DOX-induced cardiomyocyte ferroptosis and apoptosis by reducing reactive oxygen species (ROS) production and lipid peroxidation and maintaining glutathione homeostasis. BRD4770 treatment alleviated DIC without affecting the antitumor effects of DOX. Mechanistically, BRD4770 promoted nuclear factor erythroid 2-related factor 2 (Nrf2)/activating transcription factor 4 (ATF4)–solute carrier family 7 member 11 (SLC7A11) signaling and suppressed DOX-induced cardiomyocyte death by reducing methylation of lysine 9 on histone 3. Last, we constructed a ROS-responsive nanoliposome loaded with BRD4770 and conjugated with the cardiac-targeting peptide for primary cardiomyocyte, which provided better protection against DIC. These findings suggest that BRD4770 has the potential to prevent cardiomyocyte death–related cardiomyopathy.

1 July 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JLJiao Liu
Jiao Liu
YJYuxuan Jin
Yuxuan Jin
BWBei Wang
Bei Wang
YWYiran Wang
Yiran Wang
SZShengkai Zuo
Shengkai Zuo
JZJin-Ying Zhang
Jin-Ying Zhang

30 June 2025 in Circulation Research
Verified
Journal Article
Closed access
JLJiao Liu
Jiao Liu
YJYuxuan Jin
Yuxuan Jin
SZShengkai Zuo
Shengkai Zuo
CMChengsen Mu
Chengsen Mu
BWBei Wang
Bei Wang
YYYing Yu
Ying Yu
BACKGROUND: Sustained pathological cardiac hypertrophy eventually leads to heart failure; however, there is currently no effective therapeutic approach. Epigenetic dysregulation, including histone modification alterations, is implicated in cardiac hypertrophy development. Yet, the detailed mechanisms are not completely elucidated. METHODS: Nano-HPLC-MS/ms was conducted to analyze histone modifications. Cardiomyocyte-specific Dot1L (disruptor of telomeric silencing 1-like) knockout and transgenic mice were generated to evaluate the function of Dot1L in cardiac hypertrophy. Stress was induced in mice by transverse aortic constriction or continuous isoproterenol infusion. RNA-sequencing and chromatin immunoprecipitation sequencing were combined and analyzed to identify the direct transcriptional target of Dot1L, which was verified by multiple molecular biological methodologies. Primary neonatal rat ventricle myocytes were used to identify potential targets and study the molecular mechanisms. RESULTS: Histone H3K79 dimethylation and its specific methyltransferase Dot1L were upregulated in hypertrophic stimuli-treated cardiomyocytes, cardiac tissues from pressure overload–stressed mice, and patients with hypertrophic cardiomyopathy. The ablation of Dot1L in cardiomyocytes of adult mice protected against pressure overload–induced hypertrophy. Chromatin immunoprecipitation sequencing assay and genome-wide transcriptional analysis showed that Dot1L-catalyzed H3K79 dimethylation promoted the expression of transcription factor Tbx6 in stressed neonatal rat ventricle myocytes. Knockdown of Tbx6 abolished Dot1L overexpression-exaggerated cardiac hypertrophy in mice in response to pressure overload. The Dot1L inhibitor SGC0946 treatment markedly improved isoproterenol-induced cardiac hypertrophy in mice. CONCLUSIONS: Dot1L–H3K79 dimethylation–Tbx6 axis facilitates pressure overload–induced cardiac hypertrophy. Targeting Dot1L may be a promising therapeutic strategy for heart failure.

24 November 2010 in Journal of Immune Based Therapies and Vaccines
Verified
Journal Article
Open access
PDF file
SHShuhong Han
Shuhong Han
YWYichen Wang
Yichen Wang
BWBei Wang
Bei Wang
EPEkta Patel
Ekta Patel
SOStarlyn Okada
Starlyn Okada
LCLung-Ji Chang
Lung-Ji Chang
Dendritic cells (DCs) play a key role in innate and adaptive immunity but the access to sufficient amount of DCs for basic and translational research has been limited. We established a novel ex vivo system to develop and expand DCs from hematopoietic stem/progenitor cells (HPCs). Both human and mouse HPCs were expanded first in feeder culture supplemented with c-Kit ligand (KL, stem cell factor, steel factor or CD117 ligand), Flt3 ligand (fms-like tyrosine kinase 3, Flt3L, FL), thrombopoietin (TPO), IL-3, IL-6, and basic fibroblast growth factor (bFGF), and then in a second feeder culture ectopically expressing all above growth factors plus GM-CSF and IL-15. In the dual culture system, CD34+ HPCs differentiated toward DC progenitors (DCPs), which expanded more than five orders of magnitude. The DCPs showed myeloid DC surface phenotype with up-regulation of transcription factors PU.1 and Id2, and DC-related factors homeostatic chemokine ligand 17 (CCL17) and beta-chemokine receptor 6 (CCR6). Multiplex ELISA array and cDNA microarray analyses revealed that the DCPs shared some features of IL-4 and IL-15 DCs but displayed a pronounced proinflammatory phenotype. DCP-derived DCs showed antigen-uptake and immune activation functions analogous to that of the peripheral blood-derived DCs. Furthermore, bone marrow HPC-derived DCP vaccines of tumor-bearing mice suppressed tumor growth in vivo. This novel approach of generating DCP-DCs, which are different from known IL-4 and IL-15 DCs, overcomes both quantitative and qualitative limitations in obtaining functional autologous DCs from a small number of HPCs with great translational potential.

14 July 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RXRuotian Xie
Ruotian Xie
BWBei Wang
Bei Wang
SZShengkai Zuo
Shengkai Zuo
MDMei Du
Mei Du
XWXiaohong Wang
Xiaohong Wang
HYHua Yan
Hua Yan